Stockreport

HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference [Yahoo! Finance]

HUTCHMED (China) Limited - American Depositary Shares  (HCM) 
NASDAQ:AMEX Investor Relations: chi-med.com/investors/information-for-shareholders
PDF the company reported 2025 profitability (net profit $457M, including a $416M one-time divestment gain) with oncology revenue of $286M. 2026 revenue guidance of $330–$4 [Read more]